AllianceBernstein’s Day One Biopharmaceuticals DAWN Stock Holding History

AllianceBernstein’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3M	Buy	1,214,783 +1,146,993	+1,692%	+$16.2M	﹤0.01%	1146
2025 Q4	$632K	Hold	67,790	–	–	﹤0.01%	2541
2025 Q3	$478K	Hold	67,790	–	–	﹤0.01%	2706
2025 Q2	$441K	Hold	67,790	–	–	﹤0.01%	2718
2025 Q1	$538K	Sell	67,790 -210	-0.3%	-$2.26K	﹤0.01%	2525
2024 Q4	$862K	Hold	68,000	–	–	﹤0.01%	2397
2024 Q3	$947K	Hold	68,000	–	–	﹤0.01%	2355
2024 Q2	$937K	Hold	68,000	–	–	﹤0.01%	2341
2024 Q1	$1.12M	Buy	68,000 +16,500	+32%	+$247K	﹤0.01%	2202
2023 Q4	$752K	Buy	51,500 +16,430	+47%	+$199K	﹤0.01%	2408
2023 Q3	$430K	Sell	35,070 -8,240	-19%	-$107K	﹤0.01%	2646
2023 Q2	$517K	Buy	43,310 +5,910	+16%	+$77.2K	﹤0.01%	2625
2023 Q1	$500K	Sell	37,400 -4,500	-11%	-$87.9K	﹤0.01%	2577
2022 Q4	$902K	Buy	41,900 +3,900	+10%	+$80K	﹤0.01%	2335
2022 Q3	$761K	Sell	38,000 -4,400	-10%	-$93.6K	﹤0.01%	2434
2022 Q2	$759K	Buy	+42,400	New	+$438K	﹤0.01%	2488

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

AllianceBernstein's DAWN Position: Q1 2026 in Review

AllianceBernstein increased its Day One Biopharmaceuticals (DAWN) stake by 1,692% in Q1 2026, buying an estimated $16.2M and bringing the position to 1,214,783 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

AllianceBernstein first reported a position in DAWN in Q2 2022 and has held it in 16 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

AllianceBernstein held 1,214,783 shares of Day One Biopharmaceuticals worth $11.3M as of Q1 2026.
AllianceBernstein bought 1,146,993 Day One Biopharmaceuticals shares in Q1 2026, an estimated $16.2M.
Day One Biopharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1146 holding.
AllianceBernstein first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 16 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.